Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 17 clinical trials
A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer (ProHer)

This is a Phase IIIb, multinational, multicenter, randomized, open-label study to evaluate patient preference of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous use (PH FDC SC) administration in the home setting compared with the hospital setting during the cross-over period of adjuvant treatment in participants with early or …

erbb2
pertuzumab
breast-conserving surgery
mastectomy
epidermal growth factor receptor
  • 0 views
  • 11 Sep, 2023
  • 30 locations
Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer

This phase Ib/II trial tests the safety and side effects of grapiprant and eribulin and whether they work to shrink tumors in patients with inflammatory breast cancer that has spread to other

  • 0 views
  • 10 Jul, 2022
  • 1 location
Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer (PELICAN)

This phase II multicentre randomized open-label study will assess the safety and efficacy of Pembrolizumab in combination with standard chemotherapy in inflammatory breast cancer. Pembrolizumab

erbb2
paclitaxel
ejection fraction
metastasis
cish
  • 7 views
  • 06 Feb, 2022
  • 10 locations
Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer

This phase II trial studies how well radiation therapy with or without olaparib works in treating patients with inflammatory breast cancer. Radiation therapy uses high energy x-rays to kill

erbb2
cyp3a inhibitors
progesterone receptor
skin cancer
renal function
  • 77 views
  • 18 Sep, 2023
  • 151 locations
Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

This phase II trial studies how well atezolizumab, cobimetinib, and eribulin work in treating patients with inflammatory breast cancer that has spread to other places in the body (metastatic

erbb2
ejection fraction
cancer
progesterone receptor
absolute neutrophil count
  • 1 views
  • 31 Jan, 2022
  • 1 location
Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body

inflammatory breast cancer that has spread to other places in the body (metastatic). Triple-negative inflammatory breast cancer is a type of inflammatory breast cancer in which the tumor cells do not have

  • 0 views
  • 30 Jul, 2023
  • 1 location
Refining Local-Regional Therapy for IBC

nodes in patients with inflammatory breast cancer. The likelihood of identifying the sentinel lymph nodes in the operating room, using both blue dye and the radioactive substance used for

inflammatory breast cancer
breast carcinoma
carcinoma
  • 0 views
  • 04 Oct, 2022
  • 1 location
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test

This study is to learn if the combination therapy of capmatinib and neritinib can help to control metastatic or locally advanced breast cancer. Researchers also want to find the highest tolerable dose of the combination therapy of capmatinib and neritinib that can be used in this study drug combinations. The …

erbb2
advanced breast cancer
metastasis
locally advanced breast cancer
inflammatory breast cancer
  • 0 views
  • 19 Sep, 2023
  • 1 location
TRUDI: TDXD+Durva in HER2+/Low IBC (TRUDI)

treating Human Epidermal growth factor Receptor-2 (HER2)-expressing inflammatory breast cancer. The names of the study drugs involved in this study are: Trastuzumab deruxtecan

  • 0 views
  • 29 Jul, 2023
  • 2 locations
Three Fraction Radiation to Induce Immuno-Oncologic Response

Patients with high risk breast cancers (any locally advanced breast cancer patient defined as Stages IIB-III [excluding inflammatory breast cancer] with stage IIA being eligible for triple

  • 0 views
  • 18 Aug, 2021
  • 1 location